EU 505
Alternative Names: EU-505Latest Information Update: 14 Jun 2021
At a glance
- Originator Eutilex
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer